Articles related to COMBINATION THERAPY

A multiplexed cytokine and tumor-antigen mRNA immunotherapy produced durable tumor responses in mouse models of pancreatic ductal adenocarcinoma, with approximately half of treated animals remaining disease-free for up to one year, although clinical relevance remains unproven.

A phase 3 trial in extensive-stage small cell lung cancer found that adding concurrent thoracic radiotherapy to chemoimmunotherapy did not improve survival outcomes and was associated with higher toxicity. Investigators reported more adverse events and treatment-related deaths, raising safety concerns about this combination strategy.

An engineered probiotic strain delivering a modified IL-2 therapy directly within pancreatic tumors slowed tumor growth and enhanced immune activity in preclinical models. Combination studies with chemotherapy, radiotherapy, and immunotherapy showed additional activity, though human data are not yet available.

A case-based application of FRESCO trial data positions fruquintinib as a third-line option in KRAS-mutant metastatic colorectal cancer, while emphasizing treatment decisions shift toward disease control and quality of life after multiple prior lines.

Long-term follow-up from the phase 3 NRG-GY018 trial showed sustained overall survival benefit for pembrolizumab plus carboplatin-paclitaxel in dMMR endometrial cancer at 48 months, while the pMMR OS advantage did not reach statistical significance despite a 9-month median improvement.

Tafasitamab plus lenalidomide added to R-CHOP reduced the risk of progression or death by 25% compared with R-CHOP alone in previously untreated high-risk DLBCL and HGBL in a 899-patient phase 3 trial, with overall survival data not yet mature.